Search

Thousands of oncology experts from around the world will gather in Atlanta from March 29 – April 3 for the American Association for Cancer Research (AACR) Annual Meeting 2019. Memorial Sloan Kettering experts are involved in notable research presented at the meeting and are available to comment on topics including immunotherapy, precision medicine and targeted treatments, genomics, cancer interception and prevention, clinical trial design, cancer health disparities, and more. For more information and to set up interviews or access photos and video, contact [email protected] and [email protected].

… Thursday, March 28, 2019 Thousands of oncology experts from around the world will gather in Atlanta from March 29 – April 3 for the American Association for Cancer Research (AACR) Annual Meeting 2019. This year’s theme, “ Integrative   Cancer Science • Global Impact • Individualized Patient Care ,“ reinforces

A small interfering RNA implant targeting KRAS G12D/G12V mutations has shown a promising trend toward improved overall survival and objective response rate in patients with locally advanced pancreatic cancer with these mutations, according to results of a multisite, international phase 2 clinical trial led by Memorial Sloan Kettering Cancer Center.

… Thursday, January 29, 2026 A small interfering RNA (siRNA) implant targeting KRAS G12D/G12V mutations has shown a promising trend toward improved overall survival (OS) and objective response rate (ORR) in patients with locally advanced pancreatic cancer (LAPC) with these mutations, according to results

Memorial Sloan Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan Kettering's new cancer research facility, including a 23-story laboratory structure that opens this month. Mr. Zuckerman's donation is the largest single commitment by an individual in Memorial Sloan Kettering's history.

… Wednesday, May 10, 2006 Memorial Sloan Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan Kettering’s new cancer research facility, including

A study from Memorial Sloan Kettering found that young patients ages 18 to 39 with early-onset cancer have an especially high risk of harboring inherited genetic (germline) mutations.

… Monday, June 22, 2020 A study from Memorial Sloan Kettering (MSK) found that young patients ages 18 to 39 with early-onset cancer have an especially high risk of harboring inherited genetic (germline) mutations. Results from this study were presented by Zsofia K. Stadler, MD , medical oncologist at MSK

… Tuesday, February 8, 2022 2022 Black History Month Employee Profiles Carl Sanon, Assistant Manager, Outpatient Operations, Ralph Lauren Center When Carl was a junior at Binghamton University, he received an opportunity to work at MSK as a summer support intern. Initially, he saw it as a chance to make

While numerous summer student internships were cancelled this year due to the pandemic, MSK quickly modified many of our summer student programs to enroll more than 300 interns from around the world – both virtually and in-person.

… Monday, August 24, 2020 While numerous summer internships in the United States and abroad were cancelled this year due to the pandemic, Memorial Sloan Kettering (MSK) has kept many internship programs running – both virtually and in-person. This summer, more than 300 interns from around the world were

A sensitive assay for detecting tumor DNA in the blood performed well in patients and may herald the development of a blood test for cancer screening.

… Saturday, June 3, 2017 Summary Sophisticated laboratory assays for detecting and sequencing small amounts of DNA are revolutionizing biology and medicine. At ASCO, the world’s largest cancer meeting, scientists from MSK are reporting that a new and highly sensitive genomic sequencing assay can be used

This CAR T Update Part 2 summarizes the unique challenges with using CARS to defeat solid tumors, and how learning from preclinical and clinical research in hematologic malignancies is informing new strategies and research efforts.

… Thursday, June 11, 2020 New and emerging information about chimeric antigen receptor (CAR) T cell therapy in the setting of hematologic malignancies is informing strategies for overcoming obstacles in solid tumors. In our paper, published recently in the journal Expert Review of Hematology , we discuss

Learn about cryoablation for breast cancer at Memorial Sloan Kettering Cancer Center.

… Friday, October 14, 2022 Linda Dow was running out of options. The 79-year-old retired paralegal from Long Island was facing breast cancer for the second time. She had severe heart failure, which meant she was not a good candidate for breast cancer surgery . But her cancer prognosis has now improved,

Mark Awad, MD, PhD, has been appointed Chief of the Thoracic Oncology Service within the Solid Tumor Oncology Division, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).

… Friday, September 6, 2024 Mark Awad, MD, PhD , has been appointed Chief of the Thoracic Oncology Service within the Solid Tumor Oncology Division, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Dr. Awad previously served as an Associate Professor at Harvard Medical School and